FDA Granted Breakthrough Status to Adaptyx Monitor
The device designed for continuous cortisol monitoring will receive expedited review from federal regulators.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Should the FDA accelerate the approval process for innovative medical monitoring devices?
The FDA has granted Breakthrough Device Designation to a continuous cortisol monitoring platform developed by Menlo Park-based Adaptyx Biosciences. This milestone allows the Stanford University spinoff to access expedited review processes as it works to address limitations in current hormone diagnostic methods.
Why it matters
Current medical practices rely on single-time-point blood draws that often fail to capture hormone fluctuations necessary for diagnosing hypercortisolism and hypocortisolism. This new monitoring tool aims to provide continuous data to improve the management of these chronic conditions.
Adaptyx Biosciences holds an exclusive license to nine patents from Stanford University and has filed 18 additional patents since its founding. The company has secured $23 million in total seed financing to support its research efforts.
The players
Adaptyx Biosciences
A Menlo Park-based startup and Stanford University spinoff specializing in continuous molecular biosensing technology.
Stanford University
A private research university that served as the origin for the company and its foundational patent portfolio.
The details
The platform utilizes DNA-based molecular switches that change shape and emit an electrical signal when binding to target molecules in dermal interstitial fluid. This approach enables the continuous measurement of hormones, moving beyond traditional diagnostic limitations.
Timeline
September 23, 2026: The FDA announced the Breakthrough Device Designation for the platform.
Roadmap
The transition toward continuous biomarker monitoring represents a fundamental shift in endocrinology, moving away from snapshot testing to real-time physiological data. By leveraging the FDA Breakthrough Device Designation program, Adaptyx seeks to accelerate the commercialization of this diagnostic innovation.
Patients currently relying on periodic blood tests for cortisol monitoring may eventually transition to less invasive and more comprehensive wearable diagnostic options. This change could lead to more precise medication adjustments and better management of adrenal-related health conditions.
The takeaway
The move toward continuous monitoring marks a departure from static diagnostic procedures that have long hampered the treatment of hormonal imbalances. By integrating biosensing directly into the skin, the technology offers a path toward more responsive and personalized patient care.
Further reading
Learn more about the latest innovations in Biotech to understand how molecular sensing is changing medical diagnostics.
More information
Visit the Adaptyx Biosciences official website for further details on their clinical programs and technology.
Live Poll
Should the FDA accelerate the approval process for innovative medical monitoring devices?
